JDJayesh Dudhia

Jayesh Dudhia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jayesh Dudhia has a total of 317 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Senescent tenocytes drive an age-associated loss of cell-extracellular matrix homeostasis, which can be partially restored using dihydroresveratrol

    by Jack Llewellyn, Nodoka Iwasaki, Anna Hoyle, Iolanda Vendrell, Georgina Berridge, Kathryn Collins, Hollie Delo, Roger K Smith, Jayesh Dudhia, Richard G A Faragher, et al.

    Tendons are commonly injured, not only in athletes, but also during normal everyday activities, particularly in older age. Tendons are rich in extracellular matrix proteins, many of which are turned over extremely slowly during an individual's lifetime. As a result, tight regulation of the extracellular matrix is essential for tendons to remain resilient to the mechanical load placed on them. However, tendons are prone to age-associated functional decline, characterised by chronic inflammation, accumulation of damaged collagen, and matrix remodelling. These degenerative changes often precede injury, wherein additional inflammation and fibrotic tissue deposition make treatment difficult and reinjury highly likely. Understanding and preventing the causes of tendon functional decline is therefore vital to improving quality of life in the ageing population. Using an equine model, here we show that tendon fibroblasts, or tenocytes, isolated from aged tendons exhibit markers of senescence when cultured in vitro. Further, we describe how senescence in tenocytes drives inflammation, hypercontractility, and dysregulation of tendon matrix components. By replicatively senescing tenocytes isolated from young tendons, we observed that senescent tenocytes instigated proinflammatory signalling, had impaired capacity in wound healing assays, increased contractility, and secreted factors that induced senescence in healthy tenocytes. Further, tenocyte senescence dysregulated matrix turnover both at the gene and protein level. Finally, we demonstrate how senotherapeutic treatment of senescent tenocytes can reduce expression of senescence markers and restore proliferative capacity. Our results uncover systemic links between tendon ageing and cellular senescence, and identify mechanisms and therapeutic strategies for age-associated tendon degeneration.

  • Open Access

    Genes Associated With Fracture Risk in Thoroughbred Horses Have Novel Roles in Osteogenesis

    by Amy C. Ross, Ellison S. Lumsden, Caroline Flood, Jayesh Dudhia, Androniki Psifidi, Deborah J. Guest

    Bone fractures in Thoroughbred racehorses are a major welfare problem. Genetic factors contribute to fracture risk. Cell models have previously identified 112 differentially expressed genes in bone‐forming osteoblasts derived from horses at high and low genetic risk of fracture. However, 42 of these genes have no published role in bone. In this study, we identified novel roles for a subset of these genes in bone formation. Twenty‐six of the 42 genes were expressed in Saos2 cells during basal culture and/or after 21 days of osteogenic culture. Five of these genes ( ADSSL1 , CABP1 , ENO2 , SPARCL1 and UCP2 ) were then stably overexpressed and knocked down, and their effect on osteogenesis was measured. Gene overexpression resulted in significant decreases in Saos2 cell viability and decreased expression of osteogenic genes under basal cell culture, but after 21 days of osteogenic culture there were few significant changes in osteogenic gene expression, collagen deposition or matrix mineralisation. Knockdown of SPARCL1 resulted in total cell death, whereas knockdown of ADSSL1 , CABP1 , ENO2 and UCP2 resulted in decreased cell viability but limited significant changes in osteogenic gene expression under basal cell culture. However, following osteogenic culture, gene knockdown induced widespread changes in osteogenic gene expression, decreased collagen deposition and increased matrix mineralisation. ADSSL1 , CABP1 , ENO2 and UCP2 were all expressed at significantly lower levels in osteoblasts from genetically high‐risk horses. Taken together, this work demonstrates novel roles for fracture‐associated genes in bone formation and matrix mineralisation suggesting these processes may be altered in genetically susceptible horses.

  • Open Access

    Modulating Galectin-1 in human osteoblast-like cells alters mineralisation and influences the expression of genes associated with osteoblasts and osteocytes

    by Amy C. Ross, Lauren Feddersen, Jayesh Dudhia, Androniki Psifidi, Deborah J. Guest

    Bone formation, mineralisation, and remodelling are dependent on the activity of osteoblasts and osteoclasts. While many genes support bone development, their specific functions in the different stages of cell differentiation and maturation are often unknown. Galectin-1 (LGALS1) has roles in tumour angiogenesis and immune regulation but also enhances osteoblast differentiation of MSCs. The present study aimed to elucidate the role of LGALS1 in the osteogenesis of Saos2 cells. We demonstrated that Saos2 cells have a gene expression profile representing a mature osteoblast stage that shifts to an osteocyte-like profile under osteogenic conditions. We modulated LGALS1 using stable transfection to overexpress LGALS1 and lentiviral transduction of a short-hairpin RNA to knock down LGALS1. LGALS1 overexpression significantly reduced cell viability under basal culture conditions and significantly reduced mineralisation after 21 days of osteogenic culture. Knockdown of LGALS1 also significantly reduced cell viability under basal culture, but following osteogenic culture, a significant increase in mineralisation was observed. No effect on collagen deposition was seen following either knockdown or overexpression, suggesting that LGALS1 is involved in negatively regulating mineralisation. Osteogenic gene expression demonstrated few significant changes when LGALS1 was overexpressed. In contrast, knocking down LGALS1 resulted in many significant changes in osteogenic gene expression under both basal and osteogenic culture conditions. However, there was no clear correlation between the effect on gene expression and the increase in mineralisation. The present study demonstrated a novel role of LGALS1 in mature osteoblast-like cells. Further investigation into the regulatory pathways is warranted.


  • Open Access

    CRISPR/Cas9 gene editing in induced pluripotent stem cells to investigate the feline hypertrophic cardiomyopathy causing MYBPC3/R820W mutation

    by Luke C Dutton, Jayesh Dudhia, Deborah J Guest, David J Connolly

    Hypertrophic cardiomyopathy (HCM) is the most common heart disease in domestic cats, often leading to congestive heart failure and death, with current treatment strategies unable to reverse or prevent progression of the disease. The underlying pathological processes driving HCM remain unclear, which hinders novel drug discovery. The aim of this study was to generate a cellular model of the feline HCM-causing MYBPC3 mutation R820W. Using CRISPR/Cas9 gene editing we introduced the R820W mutation into a human induced pluripotent stem cell (iPSC) line. We differentiated both homozygous mutant clones and isogenic control clones to cardiomyocytes (iPSC-CMs). Protein quantification indicated that haploinsufficiency is not the disease mechanism of the mutation. Homozygous mutant iPSC-CMs had a larger cell area than isogenic controls, with the sarcomere structure and incorporation of cMyBP-C appearing similar between mutant and control iPSC-CMs. Contraction kinetic analysis indicated that homozygous iPSC-CMs have impaired relaxation and are hypocontractile compared to isogenic control iPSC-CMs. In summary, we demonstrate successful generation of an iPSC model of a feline MYBPC3 mutation, with the cellular model recapitulating aspects of HCM including cellular hypertrophy and impaired relaxation kinetics. We anticipate that further study of this model will lead to improved understanding of the disease-causing molecular mechanism, ultimately leading to novel drug discovery.


  • Open Access

    A SIRT1-independent mechanism mediates protection against steroid-induced senescence by resveralogues in equine tenocytes

    by Neda Heidari, Richard G. A. Faragher, Graham Pattison, Jayesh Dudhia, Roger K. W. Smith

    Tendinopathy is a common age-related disease which causes significant morbidity for both human athletes and performance horses. In the latter, the superficial digital flexor tendon is an excellent model for human tendinopathies because it is a functional homologue of the human Achilles tendon and a primary site of injuries with strong similarities to the human disease. Corticosteroids have been previously used clinically to treat tendinopathic inflammation, but they upregulate the p53-p21 axis with concomitant reductions in cell proliferation and collagen synthesis in human tenocytes. This phenotype is consistent with the induction of cellular senescence in vitro and in vivo and probably represents an important clinical barrier to their effective use. Because of the many differences in senescence mechanisms between species, this study aimed to evaluate these mechanisms after corticosteroid treatment in equine tenocytes. Exposure to clinically reflective levels of dexamethasone for 48 hours drove equine tenocytes into steroid induced senescence (SIS). This was characterised by permanent growth arrest and upregulation of p53, the cyclin dependent kinase inhibitors p21waf and p16ink4a as well as the matrix degrading enzymes MMP1, MMP2 and MMP13. SIS also induced a distinctive equine senescence associated secretory phenotype (eSASP) characterised by enhanced secretion of IL-8 and MCP-1. Preincubation with resveratrol or the potent SIRT1 activator SRT1720 prevented SIS in equine tenocytes, while treatment with the non-SIRT1 activating resveratrol analogue V29 was equally protective against SIS, consistent with a novel, as yet uncharacterised SIRT1-indendent mechanism which has relevance for the development of future preventative and therapeutic strategies.


  • Open Access

    Equine Embryonic Stem Cell-Derived Tenocytes are Insensitive to a Combination of Inflammatory Cytokines and Have Distinct Molecular Responses Compared to Primary Tenocytes

    by Emily J. Smith, Ross E. Beaumont, Jayesh Dudhia, Deborah J. Guest

    Tissue fibrosis following tendon injury is a major clinical problem due to the increased risk of re-injury and limited treatment options; however, its mechanism remains unclear. Evidence suggests that insufficient resolution of inflammation contributes to fibrotic healing by disrupting tenocyte activity, with the NF-κB pathway being identified as a potential mediator. Equine embryonic stem cell (ESC) derived tenocytes may offer a potential cell-based therapy to improve tendon regeneration, but how they respond to an inflammatory environment is largely unknown. Our findings reveal for the first time that, unlike adult tenocytes, ESC-tenocytes are unaffected by IFN-γ, TNFα, and IL-1β stimulation; producing minimal changes to tendon-associated gene expression and generating 3-D collagen gel constructs indistinguishable from unstimulated controls. Inflammatory pathway analysis found these inflammatory cytokines failed to activate NF-κB in the ESC-tenocytes. However, NF-κB could be activated to induce changes in gene expression following stimulation with NF-κB pharmaceutical activators. Transcriptomic analysis revealed differences between cytokine and NF-κB signalling components between adult and ESC-tenocytes, which may contribute to the mechanism by which ESC-tenocytes escape inflammatory stimuli. Further investigation of these molecular mechanisms will help guide novel therapies to reduce fibrosis and encourage superior tendon healing. Graphical Abstract


  • Open Access

    Exploration of Mediators Associated with Myocardial Remodelling in Feline Hypertrophic Cardiomyopathy

    by Wan-Ching Cheng, Charlotte Lawson, Hui-Hsuan Liu, Lois Wilkie, Melanie Dobromylskyj, Virginia Luis Fuentes, Jayesh Dudhia, David J. Connolly

    Hypertrophic cardiomyopathy (HCM) affects both humans and cats and exhibits considerable interspecies similarities that are exemplified by underlying pathological processes and clinical presentation to the extent that developments in the human field may have direct relevance to the feline disease. Characteristic changes on histological examination include cardiomyocyte hypertrophy and interstitial and replacement fibrosis. Clinically, HCM is characterised by significant diastolic dysfunction due to a reduction in ventricular compliance and relaxation associated with extracellular matrix (ECM) remodelling and the development of ventricular hypertrophy. Studies in rodent models and human HCM patients have identified key protein mediators implicated in these pathological changes, including lumican, lysyl oxidase and TGF-β isoforms. We therefore sought to quantify and describe the cellular location of these mediators in the left ventricular myocardium of cats with HCM and investigate their relationship with the quantity and structural composition of the ECM. We identified increased myocardial content of lumican, LOX and TGF-β2 mainly attributed to their increased expression within cardiomyocytes in HCM cats compared to control cats. Furthermore, we found strong correlations between the expressions of these mediators that is compatible with their role as important components of cellular pathways promoting remodelling of the left ventricular myocardium. Fibrosis and hypertrophy are important pathological changes in feline HCM, and a greater understanding of the mechanisms driving this pathology may facilitate the identification of potential therapies.


  • Open Access

    Influence of Rho/ROCK inhibitor Y-27632 on proliferation of equine mesenchymal stromal cells

    by Michaela Melzer, Janina Burk, Deborah J. Guest, Jayesh Dudhia

    Mesenchymal stromal cells (MSC) isolated form bone marrow and adipose tissue are the most common cells used for cell therapy of orthopedic diseases. MSC derived from different tissues show differences in terms of their proliferation, differentiation potential and viability in prolonged cell culture. This suggests that there may be subtle differences in intracellular signaling pathways that modulate these cellular characteristics. The Rho/ROCK signaling pathway is essential for many cellular functions. Targeting of this pathway by the ROCK inhibitor Y-27632 has been shown to be beneficial for cell viability and proliferation of different cell types. The aim of this study was to investigate the effects of Rho/ROCK inhibition on equine MSC proliferation using bone marrow-derived MSC (BMSC) and adipose-derived MSC (ASC). Primary ASC and BMSC were stimulated with or without 10 ng/mL TGF-β3 or 10 μM Y-27632, as well as both in combination. Etoposide at 10 μM was used as a positive control for inhibition of cell proliferation. After 48 h of stimulation, cell morphology, proliferation activity and gene expression of cell senescence markers p53 and p21 were assessed. ASC showed a trend for higher basal proliferation than BMSC, which was sustained following stimulation with TGF-β3. This included a higher proliferation with TGF-β3 stimulation compared to Y-27632 stimulation (p < 0.01), but not significantly different to the no treatment control when used in combination. Expression of p21 and p53 was not altered by stimulation with TGF-β3 and/or Y-27632 in either cell type. In summary, the Rho/ROCK inhibitor Y-27632 had no effect on proliferation activity and did not induce cell senescence in equine ASC and BMSC.


  • Open Access

    Transdermal drug delivery in horses: An in vitro comparison of skin structure and permeation of two model drugs at various anatomical sites

    by Samuel C. Bizley, Jayesh Dudhia, Roger K. W. Smith, Adrian C. Williams

    Background: Oral and parenteral drug delivery in horses can be difficult. Equine‐specific transdermal drug formulations offer improved ease of treatment; development of such formulations requires a deeper understanding of the structural and chemical tissue barrier of horse skin.Hypothesis/Objectives: To compare the structural composition and barrier properties of equine skin.Animals: Six warmblood horses (two males, four females) with no skin diseases.Materials and Methods: Routine histological and microscopic analyses were carried out with image analysis for skin from six different anatomical locations. In vitro drug permeation was analysed using a standard Franz diffusion cell protocol coupled with reversed phase‐high‐performance liquid chromatography detailing flux, lag times and tissue partitioning ratios of two model drug compounds.Results: Epidermal and dermal thicknesses varied between sites. The dermal and epidermal thicknesses of the croup were 1764 ± 115 μm and 36 ± 3.6 μm, respectively, and were significantly different (p < 0.05) from the inner thigh thicknesses which were 824 ± 35 μm and 49 ± 3.6 μm. Follicular density and size also varied. The highest flux for the model hydrophilic molecule (caffeine) was for the flank (3.22 ± 0.36 μg/cm2/h), while that for the lipophilic molecule (ibuprofen) was for the inner thigh (0.12 ± 0.02 μg/cm2/h).Conclusions and Clinical Relevance: Anatomical location differences in equine skin structure and small molecule permeability were demonstrated. These results can aid in the development of transdermal therapies for horses.


  • Open Access

    Intra-operative Raman spectroscopy and ex vivo Raman mapping for assessment of cartilage degradation

    by Riana Gaifulina, Abigail D.G. Nunn, Edward R.C. Draper, Robin K. Strachan, Nathan Blake, Steven Firth, Geraint M.H. Thomas, Paul F. McMillan, Jayesh Dudhia